Good cholesterol might not be such a bad idea
One of the most expensive cautionary tales in recent pharmaceutical history involves so-called good cholesterol and the idea that increasing it might ward off heart attacks and strokes. No fewer than five multinational drug companies tried and failed to turn that notion into an approved drug, and most everyone moved on.
One exception is the group behind NewAmsterdam Pharma, a company formed for the express purpose of licensing one of those failed therapies and giving it another go. Yesterday, NewAmsterdam said it had acquired the rights to Amgen’s obicetrapib and raised more than $20 million to study its effects on a narrower population than before.
This isn’t the first reclamation project for a drug like obicetrapib, which belongs to a class called CETP inhibitors. In 2018, a Canadian firm called DalCor embarked upon a Phase 3 study with dalcetrapib, a CETP inhibitor developed by Roche, enrolling 6,000 patients with a specific genetic variant. Data from that trial are expected in 2021, which is right when NewAmsterdam expects to start a large-scale study of its own, making next year a pivotal one for a class of drugs all but abandoned by the rest of the industry.
One exception is the group behind NewAmsterdam Pharma, a company formed for the express purpose of licensing one of those failed therapies and giving it another go. Yesterday, NewAmsterdam said it had acquired the rights to Amgen’s obicetrapib and raised more than $20 million to study its effects on a narrower population than before.
This isn’t the first reclamation project for a drug like obicetrapib, which belongs to a class called CETP inhibitors. In 2018, a Canadian firm called DalCor embarked upon a Phase 3 study with dalcetrapib, a CETP inhibitor developed by Roche, enrolling 6,000 patients with a specific genetic variant. Data from that trial are expected in 2021, which is right when NewAmsterdam expects to start a large-scale study of its own, making next year a pivotal one for a class of drugs all but abandoned by the rest of the industry.
.png)
No hay comentarios:
Publicar un comentario